AXL in cancer: a modulator of drug resistance and therapeutic target

被引：53

作者：

Tang, Yaoxiang ^{[1
]}

Zang, Hongjing ^{[1
]}

Wen, Qiuyuan ^{[1
]}

Fan, Songqing ^{[1
]}

机构：

[1] Cent South Univ, Xiangya Hosp 2, Dept Pathol, Changsha 410011, Hunan, Peoples R China

来源：

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2023年 / 42卷 / 01期

基金：

中国国家自然科学基金;

关键词：

AXL; Cancer; Drug resistance; Target therapy; Molecular mechanisms; RECEPTOR TYROSINE KINASE; EPITHELIAL-MESENCHYMAL TRANSITION; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; BREAST-CANCER; DNA-DAMAGE; GAS6/AXL AXIS; EGFR-TKI; INHIBITION; PROMOTES;

D O I：

10.1186/s13046-023-02726-w

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

AXL is a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinases family (RTKs), and its abnormal expression has been linked to clinicopathological features and poor prognosis of cancer patients. There is mounting evidence supporting AXL's role in the occurrence and progression of cancer, as well as drug resistance and treatment tolerance. Recent studies revealed that reducing AXL expression can weaken cancer cells' drug resistance, indicating that AXL may be a promising target for anti-cancer drug treatment. This review aims to summarize the AXL's structure, the mechanisms regulating and activating it, and its expression pattern, especially in drug-resistant cancers. Additionally, we will discuss the diverse functions of AXL in mediating cancer drug resistance and the potential of AXL inhibitors in cancer treatment.

引用

页数：14

共 113 条

[21] Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling [J].

Dong, Minhai ;

Xiao, Qungen ;

Hu, Jinyang ;

Cheng, Fangling ;

Zhang, Po ;

Zong, Weifeng ;

Tang, Qiaoying ;

Li, Xiaopeng ;

Mao, Feng ;

He, Yue ;

Yu, Xingjiang ;

Wan, Feng ;

Lei, Ting ;

Guo, Dongsheng ;

Wang, Baofeng .

CANCER GENE THERAPY, 2020, 27 (12) :878-897

[22] Does Axl have potential as a therapeutic target in pancreatic cancer? [J].

Du, Wenting ;

Brekken, Rolf A. .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2018, 22 (11) :955-966

[23] The miR-625-3p/AXL axis induces non-T790M acquired resistance to EGFR-TKI via activation of the TGF-β/Smad pathway and EMT in EGFR-mutant non-small cell lung cancer [J].

Du, Wenwen ;

Sun, Lin ;

Liu, Ting ;

Zhu, Jianjie ;

Zeng, Yuanyuan ;

Zhang, Yang ;

Wang, Xueting ;

Liu, Zeyi ;

Huang, Jian-An .

ONCOLOGY REPORTS, 2020, 44 (01) :185-195

[24] Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition [J].

Engelsen, Agnete S. T. ;

Lotsberg, Maria L. ;

Abou Khouzam, Raefa ;

Thiery, Jean-Paul ;

Lorens, James B. ;

Chouaib, Salem ;

Terry, Stephane .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[25] Giving AXL the axe: targeting AXL in human malignancy [J].

Gay, Carl M. ;

Balaji, Kavitha ;

Byers, Lauren Averett .

BRITISH JOURNAL OF CANCER, 2017, 116 (04) :415-423

[26] Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy [J].

Gourley, Charlie ;

Balmana, Judith ;

Ledermann, Jonathan A. ;

Serra, Violeta ;

Dent, Rebecca ;

Loibl, Sibylle ;

Pujade-Lauraine, Eric ;

Boulton, Simon J. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (25) :2257-+

[27] Advancement of cancer immunotherapy using nanoparticles-based nanomedicine [J].

Gowd, Vemana ;

Ahmad, Anas ;

Tarique, Mohammad ;

Suhail, Mohd ;

Zughaibi, Torki A. ;

Tabrez, Shams ;

Khan, Rehan .

SEMINARS IN CANCER BIOLOGY, 2022, 86 :624-644

[28] Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels [J].

Goyette, Marie-Anne ;

Elkholi, Islam E. ;

Apcher, Chloe ;

Kuasne, Hellen ;

Rothlin, Carla, V ;

Muller, William J. ;

Richard, Darren E. ;

Park, Morag ;

Gratton, Jean-Philippe ;

Cote, Jean-Francois .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (29)

[29] The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression [J].

Goyette, Marie-Anne ;

Duhamel, Stephanie ;

Aubert, Leo ;

Pelletier, Ariane ;

Savage, Paul ;

Thibault, Marie-Pier ;

Johnson, Radia Marie ;

Carmeliet, Peter ;

Basik, Mark ;

Gaboury, Louis ;

Muller, William J. ;

Park, Morag ;

Roux, Philippe P. ;

Gratton, Jean-Philippe ;

Cote, Jean-Francois .

CELL REPORTS, 2018, 23 (05) :1476-1490

[30] Hallmarks of Cancer: New Dimensions [J].

Hanahan, Douglas .

CANCER DISCOVERY, 2022, 12 (01) :31-46

← 1 2 3 4 5 6 7 8 9 10 →